% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • wanna_million wanna_million Dec 30, 2012 11:31 AM Flag

    Obesity Drug FGFR4

    The study is done and we should be hearing about results in a LITTLE WHILE, however long that is interpreted to be. Could it mean the first quarter 2013? This is from the December 7 transcript:

    In addition, of course we remain enthusiastic about our DGAT2 inhibitor for the treatment of nonalcoholic steatohepatitis and we are completing work on or FGFR4 inhibitor, our first peripherally acting anti-BCB agent and we will be telling you about the performance of those drugs in subsequent conversations.

    So with that, I would like to thank all of you for joining us and Erin, if you set us up for questions, I appreciate it.

    Question-and-Answer Session


    (Operator Instructions) Your first question comes from the line of Salveen Richter from Canaccord Genuity. Please proceed.

    Unidentified Analyst

    Hi, it's Andrew on for Salveen. It’s a great data today, congratulations. Just one brief question. At the end there, you mentioned the obesity drug, the FGFR4. I was just wondering about the timeframe of when we will see data from that. Thanks.

    Stanley Crooke - Chairman of the Board, President, Chief Executive Officer
    It is a very complicated study because we are looking at normal volunteers and trying to measure a variety of, particularly, FGF19, which is a difficult to measure substance. So the study has actually completed but the data analysis is taking quite a long time. Just to get all the information procedures, specialized assays. So it will be a little while. I could have just said, it will be a little while.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is more about FGFR4 from ISIS website....We should be hearing something by the end of first quarter IMO:

      ISIS-FGFR4Rx is an antisense drug that specifically reduces the production of fibroblast growth factor receptor 4, or FGFR4, in the liver and fat tissues, which decreases the body's ability to store fat while simultaneously increasing fat burning and energy expenditure. Many anti-obesity drugs act in the brain to suppress appetite, commonly resulting in central nervous systemm, or CNS, side effects. However, ISIS-FGFR4Rx does not distribute to the brain or CNS and therefore should not produce any CNS side effects.

      In preclinical studies, antisense inhibition of FGFR4 lowered body weight when we administered it as a single agent and in the presence or absence of a calorie-restricted diet. Additionally, inhibiting FGFR4 decreased body weight when we administered it in combination with an appetite-suppressing drug. In addition to reducing body weight, inhibiting FGFR4 demonstrated an improvement in insulin sensitivity. ISIS-FGFR4Rx is the first drug in our metabolic franchise to treat obesity and utilizes technology we in-licensed from Verva Pharmaceuticals Ltd.

      We are currently evaluating ISIS-FGFR4Rx in a Phase 1 study in healthy volunteers and plan to complete this study in 2012.

0.00(0.00%)Dec 21 4:00 PMEST